Version 1
: Received: 30 September 2022 / Approved: 5 October 2022 / Online: 5 October 2022 (11:29:38 CEST)
How to cite:
Wan, X.; Fagan, V.; Brennan, P.; Ebner, D. Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors. Preprints2022, 2022100038. https://doi.org/10.20944/preprints202210.0038.v1
Wan, X.; Fagan, V.; Brennan, P.; Ebner, D. Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors. Preprints 2022, 2022100038. https://doi.org/10.20944/preprints202210.0038.v1
Wan, X.; Fagan, V.; Brennan, P.; Ebner, D. Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors. Preprints2022, 2022100038. https://doi.org/10.20944/preprints202210.0038.v1
APA Style
Wan, X., Fagan, V., Brennan, P., & Ebner, D. (2022). Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors. Preprints. https://doi.org/10.20944/preprints202210.0038.v1
Chicago/Turabian Style
Wan, X., Paul Brennan and Daniel Ebner. 2022 "Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors" Preprints. https://doi.org/10.20944/preprints202210.0038.v1
Abstract
The poor success rate of preclinical drugs which target the nervous system is related to the highly complex nature of brain physiology and pathophysiology. For in vitro drug screening in this field, the two-dimensional (2D) approach - where cells are incubated in a monolayer - is not physiologically relevant. In contrast, in vivo rodent models are very low throughput and expensive. As such, improved, well-characterised three dimensional (3D) in vitro models should be employed to bridge the gap between 2D in vitro primary screening and rodent models by incorporating aspects of the in vivo brain environment. These key features include the extracellular matrix (ECM) and a multidimensional relationship of supporting cells. In this study, a neural progenitor cell line was differentiated into the main types of cells found in brain, including neurons and astrocytes. This model was designed in a 3D extracellular matrix replacement in a minimalised manner. Different culture formats using multi-well plates were explored and a high-throughput cellular imaging platform was applied. Next, we applied this model to assess neural toxicity of a newly synthesised dual-specificity tyrosine-regulated kinase 1 (DYRK1) inhibitor derived from natural compounds, which is structurally related to a natural DYRK1A inhibitor harmine, K04179. Chemical studies have already shown that K04179 has higher specificity to DYRK1A compared with previously reported DYRK1 inhibitors, such as INDY. We have produced the first report of the biological effects of this new compound on the new 3D minimalised mid-brain model with quantification of both neuronal and astrocyte populations in tandem, revealing differential toxic effects of DYRK1 inhibitor compounds K04179 and INDY on neurons and glia.
Keywords
three-dimensional in vitro model; DYRK1; human midbrain; neural progenitor cells
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
